Globus Medical

Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, announced the acquisition of Higgs Boson Health, a digital healthcare experience company based in Durham, NC and incubated out of Duke University. The acquisition aims to transform healthcare experience through AI-driven digital solutions, positioning Globus Medical to shape patient and provider experience throughout the full episode of care. Higgs Boson's team of software developers and AI scientists will join Globus Medical to power a seamless digital healthcare environment, with the goal of achieving 95% good outcomes at 10 years for all musculoskeletal surgeries. Keith Pfeil, President and CEO, stated that the Higgs Boson technology will be part of the company's surgical intelligence pillar, integrating outcomes and analytics in a closed-loop manner to foster continuous learning and improve patient outcomes.

Globus Medical is scheduled to report second-quarter 2026 results on August 6 after market close. The Zacks Consensus Estimate for revenues is $786.9 million, implying 5.6% growth from the prior year, while the consensus EPS estimate of $1.12 suggests a 30.3% increase. The company's Musculoskeletal Solutions segment is projected to grow 6.1% year over year, driven by strength in U.S. Spine, Trauma, and international markets, along with contributions from the Nevro acquisition. Enabling Technologies revenues are expected to rise 6.5% year over year, supported by adoption of the ExcelsiusGPS platform despite a shift toward leases and rentals. Globus Medical has an Earnings ESP of 0.00% and a Zacks Rank #3, indicating no clear signal for an earnings beat this quarter.

BMO Capital Markets has named Intuitive Surgical, Globus Medical, and Teleflex as its highest-conviction picks in the medical technology sector, initiating coverage with Outperform ratings and calling the beaten-down group a buying opportunity. Analyst Vik Chopra noted that MedTech stocks trade roughly 31% below their 10-year relative average, approaching the widest discount to the S&P 500 in a decade, while demand for hospital procedures remains strong. He attributed the weakness to fund flows and policy noise rather than fundamentals, describing the sector as under-owned and under-appreciated with the marginal buyer absent. Intuitive Surgical, his top pick, trades at about a 31% discount to its three-year historical multiple despite having the strongest fundamental profile among peers. Globus Medical was highlighted for sector-leading margin growth partly driven by its Nevro acquisition, and Teleflex was cited for a 2027 earnings inflection not yet reflected in consensus. Price targets were set at $518 for Intuitive Surgical, $94 for Globus Medical, and $159 for Teleflex.

Globus Medical and Medtronic have both outperformed the medical device industry over the past year, but Globus Medical shows stronger momentum and higher short-term upside. Globus Medical posted 27% year-over-year revenue growth in the first quarter, driven by double-digit gains in U.S. Spine and a 30.4% increase in Trauma, while Medtronic reported 9.9% revenue growth in its fiscal fourth quarter, supported by its Surgical & Endoscopy and Acute Care & Monitoring segments. Globus Medical remains debt-free with $560.9 million in cash and generated $202.4 million in operating cash flow, whereas Medtronic holds $9.2 billion in cash and investments but carries long-term debt after issuing $1.75 billion and repaying $2.93 billion in fiscal 2026. Based on analyst price targets, Globus Medical's average target of $109.83 implies a 29.75% upside, compared to Medtronic's average target of $96.96 representing a 20.42% increase. Zacks Investment Research rates Globus Medical a Buy and Medtronic a Sell, favoring the higher-growth, debt-free company for investors seeking stronger returns.

Globus Medical shares jumped 5.1% to $79.23 in the last trading session on higher-than-average volume, driven by investor optimism following the company's solid first-quarter 2026 performance. The medical device company posted adjusted earnings per share of $1.12 and revenues of $759.9 million, both surpassing Zacks Consensus Estimates. The consensus EPS estimate for the upcoming quarter has been revised 2.5% higher over the last 30 days, and the stock currently carries a Zacks Rank of 2, or Buy. Lucid Diagnostics, another stock in the Zacks Medical - Instruments industry, rose 9.9% to $1.08 in the same session.